Back to results
US 8,278,421 B2Granted
Human antibodies specific for gastrin materials and methods
AssigneeXoma Techolology Ltd.
InventorsLinda Masat, Marina Roell
Life of this patent
Estimating the term…
Abstract
The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression.
Claims23
An isolated antibody that binds gastrin (gastrin 17) with an affinity kd of 10−7 M or less that comprises:
- (a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NOs:
- 1, 3, 5, 7, 9, 11 or 23-33, a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution, or a consensus sequence thereof;
- (b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NOs:
- 1, 3, 5, 7, 9, 11 or 23-33, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution or a consensus sequence thereof;
- (c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NOs:
- 1, 3, 5, 7, 9, 11 or 23-33 or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution, or a consensus sequence thereof;
- (d) a light chain CDR1 amino acid sequence set forth in SEQ ID NOs:
- 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution;
- (e) a light chain CDR2 amino acid sequence set forth in SEQ ID NOs:
- 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution;
- and
- (f) a light chain CDR3 amino acid sequence set forth in SEQ ID NOs:
- 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution.
10 more elements
An isolated monoclonal antibody that binds gastrin (gastrin 17) with an affinity kd of 10−8 M or less that comprises:
- (a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NOs:
- 1, 3, 5, 7, 9, 11 or 23-33, a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution, or a consensus sequence thereof;
- (b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NOs:
- 1, 3, 5, 7, 9, 11 or 23-33, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution or a consensus sequence thereof;
- (c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NOs:
- 1, 3, 5, 7, 9, 11 or 23-33, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution, or a consensus sequence thereof;
- (d) a light chain CDR1 amino acid sequence set forth in SEQ ID NOs:
- 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution;
- (e) a light chain CDR2 amino acid sequence set forth in SEQ ID NOs:
- 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution;
- and
- (f) a light chain CDR3 amino acid sequence set forth in SEQ ID NOs:
- 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution.
10 more elements
Dependencies are inferred from the claim text.